One-Year Changes in Liver Stiffness Measurement, but not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-Term Liver Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Document Type
Article
Publication Date
1-1-2026
Abstract
Background & Aims The availability of new drugs for the treatment of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) underlines the need of early predictors of response to such therapies. This study evaluated the impact of 1-year changes in liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE), controlled attenuation parameters (CAP), and serum alanine aminotransferase (ALT) on liver outcomes in patients with MASLD. Methods A large multicenter cohort of MASLD patients with LSM ≥8 kPa and prospective follow-up was enrolled. Liver-related events (LREs), including hepatocellular carcinoma (HCC) and liver decompensation (LD), were evaluated during follow-up. LSM, CAP, ALT, and Fibrosis-4 Index (FIB-4) were assessed at baseline and at 1-year follow-up. Cause-specific Cox regression analyses were performed to correlate 1-year variation in LSM, CAP, ALT, and FIB-4 with the risk of developing LRE, LD, and HCC, in terms of cause-specific hazard ratios (csHRs). Results We included 1744 patients with LSM ≥8 kPa (median age, 55 years; 52.1% male; 58.3% obese; 55.8% with diabetes) and 989 with LSM ≥10 kPa (median age, 56 years; 50.2% male; 54.7% obese; 51% with diabetes), followed for a median of 28.2 and 32 months, respectively. LREs occurred in 39 patients with LSM ≥8 kPa (26 LD, 22 HCC) and in 35 with LSM ≥10 kPa (25 LD, 19 HCC). A 1-year variation in LSM, but not in CAP, ALT, or FIB-4, was independently associated with LRE in patients with MASLD and LSM ≥8 kPa (csHR, 1.007; 95% confidence interval [CI], 1.001–1.014). Likewise, 1-year LSM variation (csHR, 1.009; 95% CI, 1.000–1.018) independently predicted LD in this population, whereas no 1-year changes in CAP, ALT, or FIB-4 were associated with LD risk. No independent associations were observed between 1-year changes in LSM, CAP, ALT, or FIB-4 and the risk of HCC. All findings were confirmed in patients with LSM ≥10 kPa and in those at high risk of progression with type 2 diabetes. Conclusions In patients with MASLD and LSM ≥8 or ≥10 kPa, the % LSM reduction at 1 year was independently associated with lower risk of LRE and LD.
Keywords
ALT, CAP, Cirrhosis, FIB-4, Hepatocellular Carcinoma, Liver Decompensation, Liver-related Events, LSM, MASLD
Publication Title
Clinical Gastroenterology and Hepatology
ISSN
1542-3565
DOI
10.1016/j.cgh.2026.01.020
Recommended Citation
Pennisi, Grazia; Infantino, Giuseppe; Di Maria, Gabriele; Tsochatzis, Emmanuel; Bugianesi, Elisabetta; Yoneda, Masato; Zheng, Ming Hua; Hagström, Hannes; Boursier, Jérôme; Calleja, José Luis; Goh, George Boon Bee; Chan, Wah Kheong; Gallego-Durán, Rocio; Sanyal, Arun J.; de Lédinghen, Victor; Newsome, Philip N.; Fan, Jian Gao; and Castéra, Laurent, "One-Year Changes in Liver Stiffness Measurement, but not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-Term Liver Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease" (2026). Research Publications (2026 to 2030). 2129.
https://knova.um.edu.my/research_publications_2026_2030/2129
Publisher
W.B. Saunders